Gottlieb Previews Upcoming Guidances on Complex Generics

Drug Industry Daily
The FDA is working to develop and finalize a handful of new guidances on bringing complex generics to market — including complicated medicines that may require alternate methods of establishing bioequivalence, as well as drug-device combination products that may be blocked by iterative patents.

To View This Article:


Subscribe To Drug Industry Daily